Lexicon Pharmaceuticals I...

0.46
-0.00 (-0.17%)
At close: Apr 01, 2025, 3:59 PM
0.46
0.08%
After-hours: Apr 01, 2025, 07:59 PM EDT

Company Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.

Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.

The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc.

Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc. logo
Country United States
IPO Date Apr 7, 2000
Industry Biotechnology
Sector Healthcare
Employees 103
CEO Dr. Michael S. Exton Ph.D.

Contact Details

Address:
2445 Technology Forest Boulevard
The Woodlands, Texas
United States
Website https://www.lexpharma.com

Stock Details

Ticker Symbol LXRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001062822
CUSIP Number 528872302
ISIN Number US5288723027
Employer ID 76-0474169
SIC Code 2834

Key Executives

Name Position
Dr. Michael S. Exton Ph.D. Chief Executive Officer & Director
Scott M. Coiante Senior Vice President & Chief Financial Officer
Brian T. Crum Senior Vice President, General Counsel & Secretary
Carrie Siragusa Vice President of Marketing
Desiree Gendron Vice President of Sales & Training
Dixon Terry Vice President of Compliance
Dr. Alan J. Main Ph.D. Executive Vice President of Innovation & Chemical Sciences
Dr. Craig B. Granowitz M.D., Ph.D. Senior Vice President & Chief Medical Officer
Kristen L. Alexander Vice President of Finance & Accounting
Lisa M. DeFrancesco Senior Vice President of Investor Relations & Corporate Communications

Latest SEC Filings

Date Type Title
Mar 28, 2025 8-K Current Report
Mar 25, 2025 PRE 14A Filing
Mar 07, 2025 10-K Annual Report
Mar 06, 2025 8-K Current Report
Mar 03, 2025 4 Filing
Mar 03, 2025 4 Filing
Mar 03, 2025 4 Filing
Mar 03, 2025 4 Filing
Mar 03, 2025 4 Filing
Mar 03, 2025 4 Filing